Table 1.

Clinicopathological characteristics of the parent tumours from which the six PDO lines were derived.

ID	Age	Sex	Diagnosis	Nx	TRS	TNM	MMR	KRAS	BRAF
884	75	M	Adenocarcinoma	SCRT	TRS-3	pT3, N2a, M0	No loss	wt (N-RAS-mut)	wt
064	79	M	Adenocarcinoma	NA	NA	pT2, N1, M0	No loss	wt	wt
389	82	M	Adenocarcinoma	NA	NA	pT4a, N2a, M0	No loss	wt	wt
411	74	F	Adenocarcinoma	NA	NA	pT3, N2b, M0	No loss	wt	mut
653	55	F	Adenocarcinoma	NCRT	TRS-2	pT2, N0, M0	No loss	mut	wt
557	76	F	Adenocarcinoma	NA	NA	pT3, N0, M0	Loss of MLH1, PMS2 and MHS6	mut	V600E

M, male; F, female; Nx, neoadjuvant treatment; NCRT, neoadjuvant chemoradiotherapy; SCRT, short course radiotherapy; TRS, Tumour regression score; wt, wild type; mut, mutant; NA, not applicable.